Söndag 22 December | 06:43:42 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2026-01-28 08:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-17 08:00 Kvartalsrapport 2025-Q2
2025-05-06 N/A Årsstämma
2025-04-23 08:00 Kvartalsrapport 2025-Q1
2025-01-28 08:00 Bokslutskommuniké 2024
2024-10-22 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning PROB 1.30 SEK
2024-05-07 - Årsstämma
2024-04-23 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning PROB 1.30 SEK
2023-05-04 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-21 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning PROB 1.30 SEK
2022-05-05 - Årsstämma
2022-04-26 - Kvartalsrapport 2022-Q1
2022-02-02 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-07-26 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning PROB 1.10 SEK
2021-05-07 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-09 - Bokslutskommuniké 2020
2020-10-21 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning PROB 1.00 SEK
2020-05-13 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-07-19 - Kvartalsrapport 2019-Q2
2019-05-08 - X-dag ordinarie utdelning PROB 0.00 SEK
2019-05-07 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-08-13 - Kvartalsrapport 2018-Q2
2018-05-03 - X-dag ordinarie utdelning PROB 0.00 SEK
2018-05-02 - Årsstämma
2018-05-02 - Kvartalsrapport 2018-Q1
2018-01-25 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-05 - X-dag ordinarie utdelning PROB 1.00 SEK
2017-05-04 - Kvartalsrapport 2017-Q1
2017-01-24 - Bokslutskommuniké 2016
2016-10-18 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-06-29 - Extra Bolagsstämma 2016
2016-04-28 - X-dag ordinarie utdelning PROB 1.00 SEK
2016-04-27 - Årsstämma
2016-04-27 - Kvartalsrapport 2016-Q1
2016-01-26 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-07-16 - Kvartalsrapport 2015-Q2
2015-04-24 - X-dag ordinarie utdelning PROB 0.85 SEK
2015-04-23 - Årsstämma
2015-04-23 - Kvartalsrapport 2015-Q1
2015-01-28 - Bokslutskommuniké 2014
2014-10-29 - Kvartalsrapport 2014-Q3
2014-10-29 - Analytiker möte 2014
2014-08-19 - Kvartalsrapport 2014-Q2
2014-04-30 - X-dag ordinarie utdelning PROB 0.75 SEK
2014-04-29 - Årsstämma
2014-04-29 - Kvartalsrapport 2014-Q1
2014-01-23 - Bokslutskommuniké 2013
2013-10-22 - Kvartalsrapport 2013-Q3
2013-08-20 - Kvartalsrapport 2013-Q2
2013-04-25 - X-dag ordinarie utdelning PROB 0.75 SEK
2013-04-24 - Årsstämma
2013-04-24 - Kvartalsrapport 2013-Q1
2013-01-24 - Bokslutskommuniké 2012
2012-10-18 - Kvartalsrapport 2012-Q3
2012-09-28 - Kapitalmarknadsdag 2012
2012-08-16 - Kvartalsrapport 2012-Q2
2012-04-26 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-01-25 - Bokslutskommuniké 2011
2011-10-19 - Kvartalsrapport 2011-Q3
2011-07-19 - Kvartalsrapport 2011-Q2
2011-04-29 - X-dag ordinarie utdelning PROB 0.50 SEK
2011-04-29 - X-dag bonusutdelning PROB 0.5
2011-04-28 - Årsstämma
2011-04-28 - Kvartalsrapport 2011-Q1
2011-01-26 - Bokslutskommuniké 2010
2010-10-20 - Kvartalsrapport 2010-Q3
2010-07-20 - Kvartalsrapport 2010-Q2
2010-04-23 - X-dag ordinarie utdelning PROB 0.50 SEK
2010-04-22 - Årsstämma
2010-04-22 - Kvartalsrapport 2010-Q1
2010-01-27 - Bokslutskommuniké 2009
2009-10-21 - Kvartalsrapport 2009-Q3
2009-08-18 - Kvartalsrapport 2009-Q2
2009-05-07 - X-dag ordinarie utdelning PROB 0.00 SEK
2009-05-06 - Årsstämma
2009-04-22 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Probi är verksamt inom bioteknik. Bolaget är särskilt inriktade mot forskning och utveckling av probiotika, en god bakterie som återfinns i människans tarmsystem. Forskningsområdena inom bolaget innefattar mag och tarm, immunförsvar, metabola syndrom samt stress och återhämtning. Bland bolagets kunder återfinns större företagskunder inom livsmedelsindustrin. Bolaget grundades under 1991 och har sitt huvudkontor i Lund.
2024-12-13 17:17:39

The independent bid committee of Probi AB (publ) ("Probi" or the "Company") unanimously recommends the shareholders of Probi to accept the cash-based public takeover offer submitted by Symrise AG ("Symrise") on 20 November 2024.

Background

This statement is made by the independent bid committee of Probi pursuant to Nasdaq Stockholm's Takeover Rules (the "Takeover Rules").

On 20 November 2024, Probi's principal shareholder and parent company Symrise announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the "Offer").

Probi's largest shareholders after Symrise, Fjärde AP-fonden and Moneta Asset Management, respectively, representing in aggregate approximately 17.7 per cent of the outstanding capital and votes in Probi, have irrevocably undertaken to accept the Offer, subject to certain conditions.

On 26 November 2024 Symrise announced that Symrise has secured approximately 90.2 per cent of the outstanding capital and votes in Probi.

The Offer represents:

  • A premium of approximately 42 per cent compared to the closing price of SEK 246 of Probi shares on Nasdaq Stockholm on 19 November 2024, which was the last trading day prior to the announcement of the Offer;
  • A premium of approximately 31 per cent compared to the volume-weighted average share price of SEK 267 of Probi shares on Nasdaq Stockholm during the last month prior to the announcement of the Offer; and
  • A premium of approximately 33 per cent compared to the volume-weighted average share price of SEK 264 of Probi shares on Nasdaq Stockholm during the last three months prior to the announcement of the Offer.

The Offer values all 11,394,125 shares in Probi at approximately SEK 3,988 million.

The acceptance period for the Offer is expected to commence on 18 December 2024 and end on or about 15 January 2025.

Completion of the Offer is conditional upon, amongst other things, Symrise becoming the owner of more than 90 per cent of the total number of shares in Probi and the receipt of all necessary regulatory, governmental or similar clearances, approvals, decisions and other actions from authorities or similar, in each case on terms which, in Symrise's opinion, are acceptable. Symrise has reserved the right to, in whole or in part, waive these and other conditions for completion of the Offer.

For further information, please refer to Symrise's press release, www.symrise.com/probi.

The independent bid committee

In order to address matters relating to the Offer, the Board has instructed the independent members of the Board to form an independent bid committee, consisting of Charlotte Hansson, Malin Ruijsenaars and Stephanie Blum Sperisen. Due to their employment and recent employment, respectively, with the Symrise group, the chairperson of the Board of Probi, Jean-Yves Parisot, and the Board member Jörn Andreas may have conflicting interests pursuant to Rule II.18 of the Takeover Rules and are hence not part of the independent bid committee and have thus not participated in the handling of or decisions on matters related to the Offer. Accordingly, section III of the Takeover Rules is applicable on the Offer. The independent bid committee has therefore, in accordance with Rule III.3 of the Takeover Rules, requested a fairness opinion from Grant Thornton Sweden AB ("Grant Thornton"), according to which the Offer is fair from a financial point of view for the shareholders of the Company. The fairness opinion is attached to this statement. Grant Thornton receives a fixed fee for providing the fairness opinion which is not contingent upon the amount of the Offer price, the acceptance level of the Offer or whether it is completed or not.

Impact on the Company and its employees

In accordance with the Takeover Rules the independent bid committee is required, on the basis of Symrise's statement in the press release announcing the Offer, to present its opinion regarding the impact that the implementation of the Offer will have on Probi, particularly on terms of employment, and its opinion regarding Symrise's strategic plans for the Company and the effect it is anticipated that such plans will have on employment and on the locations where Probi operates. In this regard, Symrise has stated, among other things, the following:

"Symrise has strong confidence in Probi's management and employees, and believes a combination with Symrise will enable the Company to maximize its potential. Symrise, as full owner of Probi, intends to invest further in Probi, and its employees, as a key component within Symrise's focused strategy in health. Symrise does not plan any changes regarding Probi's operations or its management or employees as a result of the Offer (including employment terms and conditions) or for the locations where Probi operates."

The independent bid committee assumes that this description is accurate and has for relevant purposes no reason to adopt a different opinion.

The independent bid committee's statement on Symrise's Offer

In its evaluation of the Offer, the independent bid committee has taken a number of factors into account which they deem relevant, including, but not limited to, the Company's present strategic and financial position, prevailing market conditions and the Company's expected future development as well as opportunities and risks related thereto. The independent bid committee has considered valuation methods normally used to evaluate public offers for listed companies, including how the Offer values Probi in relation to comparable listed companies and comparable transactions, bid premiums in previous public takeover offers, the stock market's expectations regarding the Company and the independent bid committee's view of the Company's value based on its expected future cash flows.

During 2023 Probi updated its strategy and presented new financial targets, with the aim to achieve sustainable and profitable growth. The independent bid committee has full confidence in management's ability to execute on Probi's current strategy and to deliver on the Company's financial targets and acknowledges the Company's achievements to date, but also recognises that there are risks related thereto.

In particular, and in addition to the above, the independent bid committee wishes to highlight the following considerations made in connection with their evaluation of the Offer.

Considerations regarding historical trading

During the last year before the announcement of the Offer, the Probi share has not exceeded the Offer price of SEK 350 per share. The independent bid committee notes that during this period, approximately 1 per cent of the total outstanding shares in Probi has been traded on Nasdaq Stockholm, and that there generally is low liquidity in the share. The independent bid committee thus concludes that the Offer provides liquidity to the current shareholders at a level above historical prices.

Considerations regarding bid premium

The Offer represents a premium of approximately 42 per cent compared to the closing price of Probi's shares on Nasdaq Stockholm on 19 November 2024, the last trading day prior to the announcement of the Offer, and a premium of 31 per cent and 33 per cent compared to the volume-weighted average share price of Probi's shares on Nasdaq Stockholm during the last month and three months, respectively, prior to the announcement of the Offer. The independent bid committee notes that the bid premiums are in line with other announced public cash offers on Nasdaq Stockholm in recent time.

Considerations regarding the long-term value of Probi

While the independent bid committee is fully committed to Probi's current financial targets and has a positive general view on the outlook for the Company, realising the long-term value of the independent bid committee's view of Probi's future cash flows is associated with risks. The independent bid committee cannot argue that the risk adjusted long-term value potential for the Company exceeds the value of the Offer.

Implications for shareholders

The independent bid committee notes that Symrise has secured more than 90 per cent of the outstanding capital and votes in Probi in aggregate, through a combination of their own ownership, undertakings from Fjärde AP-fonden and Moneta Asset Management subject to certain conditions, and acquisitions in the market. As stated in the Offer announced by Symrise on 20 November 2024, if Symrise, whether in connection with the Offer or otherwise, acquires shares representing more than 90 per cent of the total number of capital and votes in Probi, Symrise intends to commence compulsory redemption proceedings under the Swedish Companies Act to acquire all remaining shares in Probi and to promote delisting of Probi's shares from Nasdaq Stockholm. This means that upon completion of the Offer, all shareholders, whether they tender their shares in the Offer or not, are expected to have their shares redeemed at the Offer price of SEK 350 per share. The independent bid committee notes that, in general, accepting the Offer during the acceptance period will result in the shareholder receiving the cash consideration faster than through the compulsory redemption process.

The independent bid committee has further considered the fairness opinion issued by Grant Thornton according to which the Offer is deemed fair for Probi's shareholders from a financial perspective (subject to the assumptions and considerations set forth therein).

The independent bid committee's recommendation on Symrise's Offer

In view of the above, the independent bid committee unanimously recommends the shareholders of Probi to accept the Offer.

Other

Swedish law applies to this statement and the statement shall be construed accordingly. Disputes arising pursuant to this statement are to be settled exclusively by Swedish courts.

Advisors

The independent bid committee has retained Carnegie Investment Bank AB (publ) as its financial adviser and Grant Thornton Sweden AB to render the fairness opinion and Mannheimer Swartling Advokatbyrå as its legal adviser.

For further information, please contact:

Charlotte Hansson, Chairperson of the independent bid committee, Telephone: +46 (0)73 061 20 25,

charlotte.hansson@scandinavianinsight.se